Accessing the Indian and Chinese healthcare markets: is the opportunity worth the investment?
This article was originally published in Clinica
Executive Summary
With 2011 medical device expenditures of $8.6bn and $3bn, respectively, China and India represent a growing opportunity for medtech companies. In this article, consultants* at GfK Bridgehead discuss the countries' complex and largely unregulated approval and reimbursement systems and the considerations for accessing two of the world’s key emerging markets